Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib

Abstract

A 65‐year‐old Chinese male was referred to our hospital for epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung cancer (NSCLC). Aggressive combined therapy with surgical resection of the right upper lung lesion and chemotherapy was performed. One month later, continued Icotinib treatment was used as magnetic resonance imaging revealed liver metastasis (LM). Interestingly, complete remission of the patient's LM lesions was achieved in six months. To our knowledge, this is the first report documenting a successful case of an NSCLC patient with LM treated with Icotinib after receiving a radical resection for pulmonary carcinoma. Our experience could provide a treatment strategy for patients with similar disease.

CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer

“…The epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) fusion gene are the two driver genes proved in NSCLC (8,9). Their corresponding targeted drugs, including tyrosine kinase inhibitor (TKI) and crizotinib show good curative effects in clinical studies (10,11).…”

“…In recent years, individualized treatment with molecular targeted therapy as the core content has become the research hotspot of lung cancer treatment and the detection of driver genes related to lung cancer has attracted increased attention ( 6 , 7 ). The epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) fusion gene are the two driver genes proved in NSCLC ( 8 , 9 ). Their corresponding targeted drugs, including tyrosine kinase inhibitor (TKI) and crizotinib show good curative effects in clinical studies ( 10 , 11 ).…”

Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor–Mutated Lung Cancer Treated with Two Cycles of Erlotinib

“…EGFR TKIs produce much greater response rates than standard chemotherapy in patients with EGRF mutations; however, in landmark phase III studies complete response is rare, with rates ranging from 0% to 2%. 1 There have been previous published case studies reporting complete response in patients with sustained response 2,3 ; however, they have involved much shorter time scales and the patient received maintenance treatment, whereas our patient received only two cycles and had to stop treatment because of toxicity. However, as of the time of the writing of this letter, which is 4 years since the patient stopped receiving treatment or any further anticancer medication, she has not had any recurrence of her disease.…”

“…Brendan In their article "Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors," Byrne et al 1 provide important insights into the management of immunotherapyrelated neurological adverse effects. Specifically, they make reference to a case report published by Liao et al, 2 who discuss the management of ipilimumab-induced myasthenia gravis (MG).…”

Assessment of Serum Tumor Markers for Predicting Ocular Metastasis in Lung Adenocarcinoma: A Retrospective Study

“…Lung adenocarcinoma is usually diagnosed at an advanced stage, and patients often have distant metastases [ 9 ]. The most common sites are the brain, bone, liver, and adrenal gland [ 10 , 11 ]. In the early stage, OM may have not been accompanied by ophthalmic symptoms.…”